Namilumab is under clinical development by Izana Bioscience and currently in Phase II for Axial Spondyloarthritis. According to GlobalData, Phase II drugs for Axial Spondyloarthritis have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Namilumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Namilumab overview
Namilumab (MT203, IZN-101, AMG203) is under development for the treatment of ankylosing spondylitis, axial spondyloarthritis, and cardiac sarcoidosis and pulmonary sarcoidosis. The drug candidate is administered through subcutaneous injection. It is a high-affinity IgG1 antibody. The drug candidate targets GM-CSF. It was also under development for chronic plaque psoriasis and rheumatoid arthritis.
It was under development for the treatment of coronavirus disease 2019 (COVID-19).
Izana Bioscience overview
Izana Bioscience is a biopharmaceutical company strives to the development of novel medicines for the treatment of ankylosing spondylitis (AS). Its lead product candidate, namilumab (IZN-101), is a human monoclonal antibody that targets granulocyte macrophage-colony stimulating factor (GM-CSF) for the treatment of ankylosing spondylitis, the debilitating arthritic disease of the spine. The company works in partnership with Innovate UK, which provides it a grant; and Takeda Pharmaceutical Company Ltd for in-licensing, clinical development, manufacture and commercialization of the product in all indications. Izana Bioscience is headquartered in London, England, the UK.
For a complete picture of Namilumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
